{"prompt": "['28', '11. Female subjects must be post-menopausal, surgically sterile, abstinent, or, if of child-', 'bearing potential, practicing (or agreeing to practice) an effective method of birth control', 'if they are sexually active for the duration of the study. Effective methods of birth', 'control include prescription hormonal contraceptives, intrauterine devices, double-', 'barrier methods, and/or male partner sterilization.', '12. Subject can access an internet browser in the home environment or through a smart', 'phone.', 'Enrollment Visit Inclusion Criteria', '1. Average diabetic peripheral neuropathic pain intensity (NPRS score) is > 4 and < 9', 'calculated as the mean of the daily NPRS scores for neuropathic pain in the lower', 'extremities over the 7 days preceding the visit.', '2. Subject has completed a minimum of 70% of the ePRO assessments during the run-in', 'period.', 'Exclusion Criteria', '1. Subject has an active, open ulcer on either lower extremity.', '2. Subject has significant peripheral vascular disease defined as absence of more than one-', 'foot pulse per foot and/or ABI <0.7 and >1.3 and/or history of angioplasty, peripheral', 'bypass surgery, or claudication within 6 months of the Screening Visit.', '3. Subject has venous insufficiency with an active ulcer as classified by the Venous', 'Insufficiency Classification System of grade C6.', '4.', 'Subject has a history of previous solid organ transplant or severe renal disease (i.e.', 'estimated creatinine clearance 30 mL/min).', '5. Subject has been diagnosed with a non-diabetic cause of chronic neuropathy (e.g. end', 'stage renal disease, infectious etiology, chemotherapy, drug etiology, alcohol abuse,', 'ingestion of toxic substance, nerve decompression surgery (related to lower extremity', 'symptoms), or connective tissue disease) within the past 10 years.', '6. Subject has previous or current history of primary or tertiary hyperparathyroidism,', 'hypercalcemia, psychiatric disorder, alcohol dependency, Hepatitis B or C, or HIV', 'infection.', '7. According to the judgement of the Investigator, subject has clinically significant', 'cardiovascular disease within 6 months prior to screening (unstable or poorly controlled', '710-7105-01 (', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['29', 'hypertension, transient ischemic attack, myocardial infarction, unstable angina,', 'arrhythmia, cardiac surgery, stent placement or angioplasty, or congestive heart failure).', '8. Subject has a history of any uncontrolled medical illness that, in the investigators', 'judgment, places the subject at unacceptable risk for enrollment in a research trial with', 'pulsed electromagnetic field therapy.', '9. Subject requires or anticipates the need for surgery (other than minor day surgical', 'procedures such as dental or minor cosmetic procedures not involving the lower', 'extremities and not requiring extended use of analgesics) or extended travel during the', 'treatment period.', '10. Subject has a total foot depth (most inferior aspect of the medial malleolus to the plantar', 'aspect of the foot when residing on a treatment pad) of >8 cm.', '11. Subject has received any investigational drug or device within 30 days prior to the', 'Screening Visit.', '12. Subject has received long acting lidocaine, marcaine or bupivacaine injection products', 'or other agents for nerve blocks within 6 weeks prior to the Screening Visit.', '13. Subject has used chronic systemic corticosteroid treatment within 3 months of the', 'Screening Visit.', '14. Subject has a history of malignancy within the past 5 years in the treatment area.', '15. Subject has severe mental health or psychiatric disorder of sufficient severity that would', 'interfere with study performance and/or assessments, in the opinion of the Investigator.', '16. Subject is receiving prn narcotic medications.', '17. Subject has a known history of drug or alcohol abuse within one year prior to the', 'Screening Visit.', '18. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord', 'stimulator, bone stimulator, cochlear implant, or other implanted device with an', 'implanted metal lead(s).', '19. Subject is currently pregnant or planning to become pregnant prior to Day 180.', '20. Treatment of the lower extremity with PROVANTR Therapy System.', '21. Subject is unwilling or unable to follow study instructions or comply with the treatment', 'regimen, diary documentation, and study visits.', '22. Subject has pain from any other source that can confuse the assessment of the pain', 'associated with DPN.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}